Clinical research for whether the Traditional Chinese medicine could promote the resorption of lumbar disc herniation: a randomized controlled trial

注册号:

Registration number:

ITMCTR1900002269

最近更新日期:

Date of Last Refreshed on:

2019-04-08

注册时间:

Date of Registration:

2019-04-08

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

研究中医药是否能够促进腰椎间盘突出后重吸收的随机对照临床试验

Public title:

Clinical research for whether the Traditional Chinese medicine could promote the resorption of lumbar disc herniation: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中医药促进腰椎间盘突出后重吸收的随机对照临床试验

Scientific title:

Traditional Chinese medicine promote the resorption of lumbar disc herniation: a randomized controlled trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900022377 ; ChiMCTR1900002269

申请注册联系人:

刘锦涛

研究负责人:

姜宏

Applicant:

Jintao Liu

Study leader:

Hong Jiang

申请注册联系人电话:

Applicant telephone:

+86 18934587267

研究负责人电话:

Study leader's telephone:

+86 13862557621

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

okdoctor@163.com

研究负责人电子邮件:

Study leader's E-mail:

honghong751@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省苏州市吴中西路889号苏州市中医医院

研究负责人通讯地址:

江苏省苏州市吴中西路889号苏州市中医医院

Applicant address:

889 Wuzhong Road West, Suzhou, Jiangsu, China

Study leader's address:

889 Wuzhong Road West, Suzhou, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

215009

研究负责人邮政编码:

Study leader's postcode:

215009

申请人所在单位:

苏州市中医医院

Applicant's institution:

Suzhou Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

NO.SZTCM2019-4-01

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

苏州市中医医院伦理委员会

Name of the ethic committee:

Ethic Committee Suzhou Hospital of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

陈江

Contact Name of the ethic committee:

Jiang Chen

伦理委员会联系地址:

江苏省苏州市吴中西路889号苏州市中医医院

Contact Address of the ethic committee:

Suzhou Hospital of Traditional Chinese Medicine, 889 Wuzhong Road West, Suzhou, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

苏州市中医医院

Primary sponsor:

Suzhou Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省苏州市吴中西路889号

Primary sponsor's address:

889 Wuzhong Road West, Suzhou, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

苏州

Country:

China

Province:

Jiangsu

City:

Suzhou

单位(医院):

苏州市中医医院

具体地址:

吴中西路889号

Institution
hospital:

Suzhou Hospital of Traditional Chinese Medicine

Address:

889 Wuzhong Road West

经费或物资来源:

国家自然基金面上项目(no. 81473691)

Source(s) of funding:

The present study was supported by the National Natural Science Funds of China (grant no. 81473691)

研究疾病:

腰椎间盘突出症

研究疾病代码:

Target disease:

lumbar disc herniation

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

研究中医药是否能够促进腰椎间盘突出后的重吸收。

Objectives of Study:

This clinical trial aims to study whether the Traditional Chinese medicine can promote the resorption of lumbar disc herniation, the efficacy therapy for LDH and thus confirm its clinical effect.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄20-60岁;2.疼痛VAS评分>40mm;3.最近2周内在我院确诊为腰椎间盘突出症并且有MRI图像;4.签订知情同意;5.同意在3月及6月后进行2次磁共振复查。

Inclusion criteria

(1) aged 20–60 years; (2) ≥ 40 mm pain intensity on the 100-mm pain visual analogue scale (VAS) for lower back pain; (3) having low back pain due to LDH (MRI scan confirmed lumbar disk herniation in our hospital last 2 weeks) and ruling out other relevant on going pathologies such as fractures, lumbar spondylolisthesis, tumor, osteoporosis, or infection; (4) willing to participate in this study and signing the informed consent. (5) written consent to participate in two follow-up MRI (3 month and 6 month).

排除标准:

1.有马尾神经压迫迹象患者;2.脊柱手术病史;3.有精神病;4.患有其他可能影响结果的疾病;5.准备近期怀孕的患者;6.患有研究者认为不适合纳入的疾病;7.不适合做磁共振的患者;

Exclusion criteria:

(1) red flag signs that may indicate cauda equina syndrome, such as bladder and bowel dysfunction or saddle anesthesia; (2) experiencing a history of spinal surgery; (3) having psychiatric disease; (4) having serious chronic diseases that could interfere with the outcomes; (5) pregnant or planning to become pregnant during the study; (6) having other diseases that the researchers believe is not suitable for the study; (7) patients with MRI errors or low resolution.

研究实施时间:

Study execute time:

From 2019-06-01

To      2020-06-30

征募观察对象时间:

Recruiting time:

From 2019-06-01

To      2019-12-30

干预措施:

Interventions:

组别:

中医治疗组

样本量:

75

Group:

TCM treatment group

Sample size:

干预措施:

消髓化核汤

干预措施代码:

Intervention:

TCM preparation Xiaosui Huahe decoction

Intervention code:

组别:

西医对照组

样本量:

75

Group:

Control Group

Sample size:

干预措施:

西医常规治疗

干预措施代码:

Intervention:

normal conservative treatment

Intervention code:

样本总量 Total sample size : 150

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏

市(区县):

苏州

Country:

China

Province:

Jiang Su

City:

Suzhou

单位(医院):

苏州市中医医院

单位级别:

三甲

Institution/hospital:

Suzhou Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

磁共振成像

指标类型:

主要指标

Outcome:

Imaging Results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

100-mm VAS for pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Oswestry功能障碍指数

指标类型:

次要指标

Outcome:

Oswestry Disability Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 20
Min age years
最大 60
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

通过SPSS 16.0软件产生随机数字,将受试者按1:1比例随机分配到实验组与对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

In this trial, participants will be randomly assigned to either the tuina group or the ibuprofen group in a 1:1 ratio using a random number generator (SPSS 16.0, SPSS Inc, Chicago, IL, USA).

盲法:

open

Blinding:

open

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2020-11 Published article

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above